Lactate regulates cell cycle by remodeling the anaphase promoting complex. Nature. 2023 Mar 15.
View in:
PubMed
Targeting tumor-associated macrophages with STING agonism improves the antitumor efficacy of osimertinib in a mouse model of EGFR-mutant lung cancer. Front Immunol. 2023; 14:1077203.
View in:
PubMed
PI(3,5)P 2 Controls the Signaling Activity of Class I PI3K. bioRxiv. 2023 Jan 25.
View in:
PubMed
Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases. Clin Cancer Res. 2023 01 04; 29(1):174-182.
View in:
PubMed
STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancer. J Immunother Cancer. 2023 01; 11(1).
View in:
PubMed
Targeting oncogenic KRAS with molecular brush-conjugated antisense oligonucleotides. Proc Natl Acad Sci U S A. 2022 07 19; 119(29):e2113180119.
View in:
PubMed
STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer. Nat Commun. 2022 05 31; 13(1):3022.
View in:
PubMed
Maximizing TLR9 Activation in Cancer Immunotherapy with Dual-Adjuvanted Spherical Nucleic Acids. Nano Lett. 2022 05 25; 22(10):4058-4066.
View in:
PubMed
Blocking PI3K p110ß Attenuates Development of PTEN-Deficient Castration-Resistant Prostate Cancer. Mol Cancer Res. 2022 05 04; 20(5):673-685.
View in:
PubMed
p16INK4A-deficiency predicts response to combined HER2 and CDK4/6 inhibition in HER2+ breast cancer brain metastases. Nat Commun. 2022 03 18; 13(1):1473.
View in:
PubMed
Targeting CDK4 and CDK6 in cancer. Nat Rev Cancer. 2022 06; 22(6):356-372.
View in:
PubMed
Temporal and spatial topography of cell proliferation in cancer. Nat Cell Biol. 2022 03; 24(3):316-326.
View in:
PubMed
Methylene-bridge tryptophan fatty acylation regulates PI3K-AKT signaling and glucose uptake. Cell Rep. 2022 03 15; 38(11):110509.
View in:
PubMed
Sarm1 activation produces cADPR to increase intra-axonal Ca++ and promote axon degeneration in PIPN. J Cell Biol. 2022 02 07; 221(2).
View in:
PubMed
How Compensatory Mechanisms and Adaptive Rewiring Have Shaped Our Understanding of Therapeutic Resistance in Cancer. Cancer Res. 2021 12 15; 81(24):6074-6077.
View in:
PubMed
Disrupted PI3K subunit p110a signaling protects against pulmonary hypertension and reverses established disease in rodents. J Clin Invest. 2021 10 01; 131(19).
View in:
PubMed
Lacrimal gland budding requires PI3K-dependent suppression of EGF signaling. Sci Adv. 2021 Jun; 7(27).
View in:
PubMed
The role of the PIK3CA gene in the development and aging of the brain. Sci Rep. 2021 01 11; 11(1):291.
View in:
PubMed
CDK4/6 inhibition reprograms the breast cancer enhancer landscape by stimulating AP-1 transcriptional activity. Nat Cancer. 2021 01; 2(1):34-48.
View in:
PubMed
Divergent Roles of PI3K Isoforms in PTEN-Deficient Glioblastomas. Cell Rep. 2020 09 29; 32(13):108196.
View in:
PubMed
PIK3CA C-terminal frameshift mutations are novel oncogenic events that sensitize tumors to PI3K-a inhibition. Proc Natl Acad Sci U S A. 2020 09 29; 117(39):24427-24433.
View in:
PubMed
A sequential methodology for the rapid identification and characterization of breast cancer-associated functional SNPs. Nat Commun. 2020 07 03; 11(1):3340.
View in:
PubMed
Integrating Immunotherapy and Targeted Therapy in Cancer Treatment: Mechanistic Insights and Clinical Implications. Clin Cancer Res. 2020 11 01; 26(21):5557-5566.
View in:
PubMed
Limited Environmental Serine and Glycine Confer Brain Metastasis Sensitivity to PHGDH Inhibition. Cancer Discov. 2020 09; 10(9):1352-1373.
View in:
PubMed
Increased lysosomal biomass is responsible for the resistance of triple-negative breast cancers to CDK4/6 inhibition. Sci Adv. 2020 06; 6(25):eabb2210.
View in:
PubMed
High-throughput dynamic BH3 profiling may quickly and accurately predict effective therapies in solid tumors. Sci Signal. 2020 06 16; 13(636).
View in:
PubMed
Inhibition of the transcriptional kinase CDK7 overcomes therapeutic resistance in HER2-positive breast cancers. Oncogene. 2020 01; 39(1):50-63.
View in:
PubMed
PI3 kinase alpha and delta promote hematopoietic stem cell activation. JCI Insight. 2019 05 23; 5.
View in:
PubMed
Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial. J Clin Oncol. 2019 03 20; 37(9):741-750.
View in:
PubMed
Improving orthotopic mouse models of patient-derived breast cancer brain metastases by a modified intracarotid injection method. Sci Rep. 2019 01 24; 9(1):622.
View in:
PubMed
PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer. Cell Rep. 2018 12 11; 25(11):2972-2980.e5.
View in:
PubMed
Targeted Profiling of RNA Translation. Curr Protoc Mol Biol. 2019 01; 125(1):e71.
View in:
PubMed
A Conditional Dependency on MELK for the Proliferation of Triple-Negative Breast Cancer Cells. iScience. 2018 Nov 30; 9:149-160.
View in:
PubMed
Structure-Based Drug Design and Identification of H2O-Soluble and Low Toxic Hexacyclic Camptothecin Derivatives with Improved Efficacy in Cancer and Lethal Inflammation Models in Vivo. J Med Chem. 2018 10 11; 61(19):8613-8624.
View in:
PubMed
BRCA1-IRIS promotes human tumor progression through PTEN blockade and HIF-1a activation. Proc Natl Acad Sci U S A. 2018 10 09; 115(41):E9600-E9609.
View in:
PubMed
Targeted profiling of RNA translation reveals mTOR-4EBP1/2-independent translation regulation of mRNAs encoding ribosomal proteins. Proc Natl Acad Sci U S A. 2018 10 02; 115(40):E9325-E9332.
View in:
PubMed
An alternative splicing switch in FLNB promotes the mesenchymal cell state in human breast cancer. Elife. 2018 07 30; 7.
View in:
PubMed
CDK4/6 Inhibition in Cancer: Beyond Cell Cycle Arrest. Trends Cell Biol. 2018 11; 28(11):911-925.
View in:
PubMed
Dual HDAC and PI3K Inhibition Abrogates NF?B- and FOXM1-Mediated DNA Damage Response to Radiosensitize Pediatric High-Grade Gliomas. Cancer Res. 2018 07 15; 78(14):4007-4021.
View in:
PubMed
Correction: MELK is an oncogenic kinase essential for mitotic progression in basal-like breast cancer cells. Elife. 2018 03 12; 7.
View in:
PubMed
Isoform-Selective Phosphatidylinositol 3-Kinase Inhibition in Cancer. J Clin Oncol. 2018 05 01; 36(13):1339-1342.
View in:
PubMed
Oncogenic Kinase-Induced PKM2 Tyrosine 105 Phosphorylation Converts Nononcogenic PKM2 to a Tumor Promoter and Induces Cancer Stem-like Cells. Cancer Res. 2018 05 01; 78(9):2248-2261.
View in:
PubMed
Allele-Specific Chromatin Recruitment and Therapeutic Vulnerabilities of ESR1 Activating Mutations. Cancer Cell. 2018 02 12; 33(2):173-186.e5.
View in:
PubMed
Drug Resistance in HER2-Positive Breast Cancer Brain Metastases: Blame the Barrier or the Brain? Clin Cancer Res. 2018 04 15; 24(8):1795-1804.
View in:
PubMed
Oridonin inhibits aberrant AKT activation in breast cancer. Oncotarget. 2018 May 08; 9(35):23878-23889.
View in:
PubMed
Pik3ca is required for mouse uterine gland development and pregnancy. PLoS One. 2018; 13(1):e0191433.
View in:
PubMed
PI3Ka inactivation in leptin receptor cells increases leptin sensitivity but disrupts growth and reproduction. JCI Insight. 2017 12 07; 2(23).
View in:
PubMed
Targeting neuronal activity-regulated neuroligin-3 dependency in high-grade glioma. Nature. 2017 09 28; 549(7673):533-537.
View in:
PubMed
MELK is not necessary for the proliferation of basal-like breast cancer cells. Elife. 2017 09 19; 6.
View in:
PubMed
CDK4/6 inhibition triggers anti-tumour immunity. Nature. 2017 08 24; 548(7668):471-475.
View in:
PubMed
CRKL Mediates p110ß-Dependent PI3K Signaling in PTEN-Deficient Cancer Cells. Cell Rep. 2017 07 18; 20(3):549-557.
View in:
PubMed
PI3K-p110a mediates the oncogenic activity induced by loss of the novel tumor suppressor PI3K-p85a. Proc Natl Acad Sci U S A. 2017 07 03; 114(27):7095-7100.
View in:
PubMed
Cell-Cycle-Targeting MicroRNAs as Therapeutic Tools against Refractory Cancers. Cancer Cell. 2017 04 10; 31(4):576-590.e8.
View in:
PubMed
The emerging role of PI3K/AKT-mediated epigenetic regulation in cancer. Biochim Biophys Acta Rev Cancer. 2017 Aug; 1868(1):123-131.
View in:
PubMed
Targeting of Ras-mediated FGF signaling suppresses Pten-deficient skin tumor. Proc Natl Acad Sci U S A. 2016 11 15; 113(46):13156-13161.
View in:
PubMed
Rac1-mediated membrane raft localization of PI3K/p110ß is required for its activation by GPCRs or PTEN loss. Elife. 2016 10 04; 5.
View in:
PubMed
NTRK2 activation cooperates with PTEN deficiency in T-ALL through activation of both the PI3K-AKT and JAK-STAT3 pathways. Cell Discov. 2016; 2:16030.
View in:
PubMed
Mitotic MELK-eIF4B signaling controls protein synthesis and tumor cell survival. Proc Natl Acad Sci U S A. 2016 08 30; 113(35):9810-5.
View in:
PubMed
CDK4/6 inhibition: the late harvest cycle begins. Oncotarget. 2016 08 02; 7(31):48854-48856.
View in:
PubMed
Discovery of a Series of 5,11-Dihydro-6H-benzo[e]pyrimido[5,4-b][1,4]diazepin-6-ones as Selective PI3K-d/? Inhibitors. ACS Med Chem Lett. 2016 Oct 13; 7(10):908-912.
View in:
PubMed
Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes. Gynecol Oncol. 2016 09; 142(3):548-56.
View in:
PubMed
Tyrosine receptor kinase B is a drug target in astrocytomas. Neuro Oncol. 2017 01; 19(1):22-30.
View in:
PubMed
PI3K/AKT Signaling Regulates H3K4 Methylation in Breast Cancer. Cell Rep. 2016 06 21; 15(12):2692-704.
View in:
PubMed
Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases. Nat Med. 2016 07; 22(7):723-6.
View in:
PubMed
A cell-based quantitative high-throughput image screening identified novel autophagy modulators. Pharmacol Res. 2016 08; 110:35-49.
View in:
PubMed
PI3K in the ventromedial hypothalamic nucleus mediates estrogenic actions on energy expenditure in female mice. Sci Rep. 2016 Mar 18; 6:23459.
View in:
PubMed
Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer. Oncotarget. 2016 Mar 15; 7(11):13153-66.
View in:
PubMed
Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors. Cancer Cell. 2016 Mar 14; 29(3):255-269.
View in:
PubMed
Corrigendum: Essential roles of PI(3)K-p110ß in cell growth, metabolism and tumorigenesis. Nature. 2016 05 12; 533(7602):278.
View in:
PubMed
Mouse models of human PIK3CA-related brain overgrowth have acutely treatable epilepsy. Elife. 2015 Dec 03; 4.
View in:
PubMed
Modeling human PIK3CA-related congenital brain overgrowth and epilepsy in mice. Int J Dev Neurosci. 2015 Dec; 47(Pt A):46.
View in:
PubMed
A PI3K p110ß-Rac signalling loop mediates Pten-loss-induced perturbation of haematopoiesis and leukaemogenesis. Nat Commun. 2015 Oct 07; 6:8501.
View in:
PubMed
CDK7-dependent transcriptional addiction in triple-negative breast cancer. Cell. 2015 Sep 24; 163(1):174-86.
View in:
PubMed
The ERa-PI3K Cascade in Proopiomelanocortin Progenitor Neurons Regulates Feeding and Glucose Balance in Female Mice. Endocrinology. 2015 Dec; 156(12):4474-91.
View in:
PubMed
Bioprinting for cancer research. Trends Biotechnol. 2015 Sep; 33(9):504-13.
View in:
PubMed
Light-triggered, self-immolative nucleic Acid-drug nanostructures. J Am Chem Soc. 2015 May 20; 137(19):6112-5.
View in:
PubMed
Class IA Phosphatidylinositol 3-Kinase Isoform p110a Mediates Vascular Remodeling. Arterioscler Thromb Vasc Biol. 2015 Jun; 35(6):1434-44.
View in:
PubMed
Chemopreventive effects of aspirin at a glance. Biochim Biophys Acta. 2015 Apr; 1855(2):254-63.
View in:
PubMed
Role of phosphoinositide 3-OH kinase p110ß in skeletal myogenesis. Mol Cell Biol. 2015 Apr; 35(7):1182-96.
View in:
PubMed
PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. Nat Rev Cancer. 2015 Jan; 15(1):7-24.
View in:
PubMed
Measurement of PIP3 levels reveals an unexpected role for p110ß in early adaptive responses to p110a-specific inhibitors in luminal breast cancer. Cancer Cell. 2015 Jan 12; 27(1):97-108.
View in:
PubMed
Cyclin C is a haploinsufficient tumour suppressor. Nat Cell Biol. 2014 Nov; 16(11):1080-91.
View in:
PubMed
MELK is an oncogenic kinase essential for mitotic progression in basal-like breast cancer cells. Elife. 2014 May 20; 3:e01763.
View in:
PubMed
PI3K isoform dependence of PTEN-deficient tumors can be altered by the genetic context. Proc Natl Acad Sci U S A. 2014 Apr 29; 111(17):6395-400.
View in:
PubMed
Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110a. J Clin Invest. 2014 Apr; 124(4):1794-809.
View in:
PubMed
A genetic mouse model of invasive endometrial cancer driven by concurrent loss of Pten and Lkb1 Is highly responsive to mTOR inhibition. Cancer Res. 2014 Jan 01; 74(1):15-23.
View in:
PubMed
The gene dosage of class Ia PI3K dictates the development of PTEN hamartoma tumor syndrome. Cell Cycle. 2013 Dec 01; 12(23):3589-93.
View in:
PubMed
Coordinate activation of Shh and PI3K signaling in PTEN-deficient glioblastoma: new therapeutic opportunities. Nat Med. 2013 Nov; 19(11):1518-23.
View in:
PubMed
Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies. Proc Natl Acad Sci U S A. 2013 Aug 27; 110(35):14372-7.
View in:
PubMed
Spatially distinct roles of class Ia PI3K isoforms in the development and maintenance of PTEN hamartoma tumor syndrome. Genes Dev. 2013 Jul 15; 27(14):1568-80.
View in:
PubMed
Central GLP-2 enhances hepatic insulin sensitivity via activating PI3K signaling in POMC neurons. Cell Metab. 2013 Jul 02; 18(1):86-98.
View in:
PubMed
Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling. Cancer Res. 2013 Jul 01; 73(13):4075-85.
View in:
PubMed
Opposing effects of androgen deprivation and targeted therapy on prostate cancer prevention. Cancer Discov. 2013 Jan; 3(1):44-51.
View in:
PubMed
The p110a and p110ß isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis. Genes Dev. 2012 Jul 15; 26(14):1573-86.
View in:
PubMed
Functional characterization of an isoform-selective inhibitor of PI3K-p110ß as a potential anticancer agent. Cancer Discov. 2012 May; 2(5):425-33.
View in:
PubMed
Kinome-wide selectivity profiling of ATP-competitive mammalian target of rapamycin (mTOR) inhibitors and characterization of their binding kinetics. J Biol Chem. 2012 Mar 23; 287(13):9742-9752.
View in:
PubMed
Lysosomal transmembrane protein LAPTM4B promotes autophagy and tolerance to metabolic stress in cancer cells. Cancer Res. 2011 Dec 15; 71(24):7481-9.
View in:
PubMed
The acute effects of leptin require PI3K signaling in the hypothalamic ventral premammillary nucleus. J Neurosci. 2011 Sep 14; 31(37):13147-56.
View in:
PubMed
Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms. Nat Med. 2011 Aug 07; 17(9):1116-20.
View in:
PubMed
Therapeutic implications of GIPC1 silencing in cancer. PLoS One. 2010 Dec 30; 5(12):e15581.
View in:
PubMed
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature. 2010 Dec 16; 468(7326):968-72.
View in:
PubMed
PI3K signaling in the ventromedial hypothalamic nucleus is required for normal energy homeostasis. Cell Metab. 2010 Jul 07; 12(1):88-95.
View in:
PubMed
Specific roles of the p110alpha isoform of phosphatidylinsositol 3-kinase in hepatic insulin signaling and metabolic regulation. Cell Metab. 2010 Mar 03; 11(3):220-30.
View in:
PubMed
Estrogen receptor-negative breast cancer: new insights into subclassification and targeting. Clin Cancer Res. 2009 Oct 15; 15(20):6309-10.
View in:
PubMed
Phosphatidyl inositol 3-kinase signaling in hypothalamic proopiomelanocortin neurons contributes to the regulation of glucose homeostasis. Endocrinology. 2009 Nov; 150(11):4874-82.
View in:
PubMed
Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009 Aug; 8(8):627-44.
View in:
PubMed
SIK1 couples LKB1 to p53-dependent anoikis and suppresses metastasis. Sci Signal. 2009 Jul 21; 2(80):ra35.
View in:
PubMed
3-Phosphoinositide-dependent kinase 1 potentiates upstream lesions on the phosphatidylinositol 3-kinase pathway in breast carcinoma. Cancer Res. 2009 Aug 01; 69(15):6299-306.
View in:
PubMed
Should individual PI3 kinase isoforms be targeted in cancer? Curr Opin Cell Biol. 2009 Apr; 21(2):199-208.
View in:
PubMed
Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature. 2008 Aug 07; 454(7205):776-9.
View in:
PubMed
Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell. 2007 Jun 15; 129(6):1065-79.
View in:
PubMed
Surveillance mechanism linking Bub1 loss to the p53 pathway. Proc Natl Acad Sci U S A. 2007 May 15; 104(20):8334-9.
View in:
PubMed
The p110alpha isoform of phosphatidylinositol 3-kinase is essential for polyomavirus middle T antigen-mediated transformation. J Virol. 2007 Jul; 81(13):7069-76.
View in:
PubMed
PI3 kinases in cancer: from oncogene artifact to leading cancer target. Sci STKE. 2006 Dec 12; 2006(365):pe52.
View in:
PubMed
The p110alpha isoform of PI3K is essential for proper growth factor signaling and oncogenic transformation. Proc Natl Acad Sci U S A. 2006 Oct 31; 103(44):16296-300.
View in:
PubMed
The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells. Proc Natl Acad Sci U S A. 2005 Dec 20; 102(51):18443-8.
View in:
PubMed
A genetic screen for candidate tumor suppressors identifies REST. Cell. 2005 Jun 17; 121(6):837-48.
View in:
PubMed
Androgen-induced differentiation and tumorigenicity of human prostate epithelial cells. Cancer Res. 2004 Dec 15; 64(24):8867-75.
View in:
PubMed
Functional genetics and experimental models of human cancer. Trends Mol Med. 2004 Jul; 10(7):344-50.
View in:
PubMed
Simian virus 40 large T antigen targets the spindle assembly checkpoint protein Bub1. Proc Natl Acad Sci U S A. 2004 Jan 27; 101(4):947-52.
View in:
PubMed
A chemical genetic screen identifies inhibitors of regulated nuclear export of a Forkhead transcription factor in PTEN-deficient tumor cells. Cancer Cell. 2003 Dec; 4(6):463-76.
View in:
PubMed
Human mammary epithelial cell transformation through the activation of phosphatidylinositol 3-kinase. Cancer Cell. 2003 May; 3(5):483-95.
View in:
PubMed